 The review highlights four methods that reduce ischemia reperfusion, IR, injury during liver transplantation, including pre- and post-conditioning pharmacological intervention, and future Myrna gene therapy. These therapies activate serine-threnine kinase act, which promote cellular survival and reduces hepatocyte damage. The review suggests that these therapies could potentially be used in combination to achieve better outcomes in hepatic transplant patients, but further studies in human clinical trials are needed to confirm their effectiveness. This article was authored by Stephen M. Covington, Laura D. Baller, and Luis H. Toledo Pereira.